Engineers Gate Manager’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Engineers Gate Manager’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,619	Closed	-$20.6K	–	2620
2025 Q3	$20.6K	Buy	13,619 +598	+5%	+$896	﹤0.01%	2099
2025 Q2	$15.1K	Buy	+13,021	New	+$17.2K	﹤0.01%	2101
2025 Q1	–	Sell	-17,949	Closed	-$54.4K	–	2638
2024 Q4	$54.4K	Buy	+17,949	New	+$58.8K	﹤0.01%	2076
2024 Q3	–	Sell	-14,637	Closed	-$59.9K	–	2455
2024 Q2	$59.9K	Sell	14,637 -10,975	-43%	-$123K	﹤0.01%	1802
2024 Q1	$404K	Buy	+25,612	New	+$352K	0.01%	1310
2023 Q4	–	Sell	-22,611	Closed	-$454K	–	2308
2023 Q3	$454K	Buy	+22,611	New	+$574K	0.02%	1098

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Engineers Gate Manager's ZNTL Position: Q4 2025 in Review

Engineers Gate Manager sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 13,619 shares — an estimated $20.6K sold.

Engineers Gate Manager first reported a position in ZNTL in Q3 2023 and held it in 6 quarters. The position peaked at $454K in Q3 2023. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

Engineers Gate Manager reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Engineers Gate Manager sold 13,619 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $20.6K.
Engineers Gate Manager first reported a position in Zentalis Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Engineers Gate Manager's Zentalis Pharmaceuticals position peaked at $454K in Q3 2023.
86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Engineers Gate Manager's 13F filing for Q4 2025, filed 17 Feb 2026.